pharmaceutical investing Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
pharmaceutical investing Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia
pharmaceutical investing Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
pharmaceutical investing Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
pharmaceutical investing Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
pharmaceutical investing Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
pharmaceutical investing Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
pharmaceutical investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement